Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To assess the relationship of WT1 mutations vis-à-vis beta-catenin mutations in Wilms tumor, we analyzed 153 primary tumors, and 21 of 153 (14%) carried beta-catenin mutations.
|
11103785 |
2000 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Implication of beta-catenin mutations in WT was investigated in 24 tumors collected from 20 WT patients.
|
12239584 |
2002 |
Nephroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study has analysed the intracellular levels and subcellular distribution of beta-catenin protein in 36 primary Wilms' tumour specimens and has correlated these results with the mutational status of the beta-catenin gene.
|
12474228 |
2003 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, as the beta-catenin mutation is frequently associated with the WT1 mutation, the association of WT1 silencing with the beta-catenin mutation was also investigated. beta-catenin mutated in only one WT without WT1 silencing, suggesting that the beta-catenin mutation was not associated with the reduction of WT1 expression.
|
12761165 |
2003 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin.
|
14666652 |
2004 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Microsatellite analysis of APC and immunoexpression of beta catenin did not provide significant pathological or prognostic information in this cohort of nephroblastomas.
|
15623481 |
2005 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This overlap in mutation pattern of WT1 and beta-catenin in Wilms' tumor suggests that these 2 genes may collaborate in the genesis of a subset of Wilms' tumors.
|
15540161 |
2005 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Deregulation of the Wnt signalling pathway is a key event in the development of a broad spectrum of human malignancies and mutations in beta-catenin (CTNNB1), a central component of the Wnt pathway, have been detected in 10-15% of Wilms tumors (nephroblastoma).
|
15737694 |
2005 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytoplasmic beta-catenin accumulation was demonstrated in two papillary carcinomas, one neuroblastoma-associated carcinoma, and two carcinomas arising from nephroblastoma.
|
17873895 |
2007 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemistry was also performed to investigate how the mutations in beta-catenin alter the localisation in Wilms tumour development.
|
17172473 |
2007 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
|
18618575 |
2008 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on characterization of both genomic and expression status of WT1 and CTNNB1 (beta-catenin) in a series of 60 Wilms tumor samples, combined with genome-wide expression profiling of these tumors, normal mature and fetal kidney controls, we show that WT1/beta-catenin expression was a better classifier than WT1/CTNNB1 mutations.
|
19530245 |
2009 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Canonical WNT signalling determines lineage specificity in Wilms tumour.
|
19137020 |
2009 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Wilms' tumor (WT), the most common pediatric renal malignancy, is associated with mutations in several well-characterized genes, most notably WT1, CTNNB1, WTX, and TP53.
|
20332316 |
2010 |
Nephroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Introduction of a stabilizing β-catenin mutation restricted to the kidney is sufficient to induce primitive renal epithelial tumors; however, when compounded with activation of K-RAS, the mice develop large, bilateral, metastatic, multifocal primitive renal epithelial tumors that have the histologic and staining characteristics of the epithelial component of human WT.
|
21983638 |
2011 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
GS expression was not observed in CTNNB1-mutated nephroblastoma.
|
21237236 |
2011 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genes identified as being mutated in Wilms' tumour include TP53, a classic tumour suppressor gene (TSG); CTNNB1 (encoding β-catenin), a classic oncogene; WTX, which accumulating data indicate is a TSG; and WT1, which is inactivated in some Wilms' tumours, similar to a TSG.
|
21248786 |
2011 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
One blastema-type nephroblastoma showed nuclear localisation of β-catenin in conjunction with LOH of the APC gene.
|
22081130 |
2011 |
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GS expression was not observed in CTNNB1-mutated nephroblastoma.
|
21237236 |
2011 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, FZD7-resistant WT in which no cell death was induced showed a different intra-cellular route of the Ab-FZD7 complex compared with sensitive tumors and accumulation of β-catenin.
|
21472018 |
2011 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abnormalities of WT1, WTX and CTNNB1, and loss of IGF2 imprinting (LOI) were detected in 31.6%, 22.8%, 26.3%, and 21.1% of the 114 WTs, respectively.
|
22409817 |
2012 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The 17.94 cell line contained a TP53 mutation, consistent with the anaplastic histology of the original tumor, but lacked mutations in WT1, WTX, or CTNNB1, which are the other genes involved in WT pathogenesis.
|
22749038 |
2012 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other genes frequently altered somatically in subsets of WT are CTNNB1 and WTX; both genes influence the Wnt signalling pathway.
|
22461142 |
2013 |
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/β-catenin pathway in Wilms tumorigenesis.
|
24258344 |
2013 |
Nephroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Somatic mutations in exon 3 of CTNNB1, which encodes β-catenin, were initially observed in 15% of WT.
|
23117548 |
2013 |